Fresh Tracks Therapeutics, Inc. financial data

Symbol
FRTX on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
2000 Central Avenue, Suite 100, Boulder, CO
State of incorporation
DE
Fiscal year end
December 31
Former names
Brickell Biotech, Inc. (to 9/6/2022), VICAL INC (to 8/30/2019), VICAL, INC. (to 2/11/1994)
Latest financial report
10-K - Q4 2023 - Mar 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 597 % +31.3%
Return On Equity -58.8 % +65.1%
Return On Assets -49 % +62.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.97M shares +1.13%
Common Stock, Shares, Outstanding 5.97M shares +97.9%
Entity Public Float 4.1M USD -72.5%
Common Stock, Value, Issued 60K USD +100%
Weighted Average Number of Shares Outstanding, Basic 5.39M shares +92.1%
Weighted Average Number of Shares Outstanding, Diluted 5.39M shares +92.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.01M USD +15.3%
Research and Development Expense 3.18M USD -77.3%
General and Administrative Expense 11.2M USD -22.5%
Operating Income (Loss) -6.36M USD +70.5%
Net Income (Loss) Attributable to Parent -5.69M USD +73%
Earnings Per Share, Basic -1.06 USD/shares +85.9%
Earnings Per Share, Diluted -1.06 USD/shares +85.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.9M USD +25.2%
Other Assets, Current 7K USD -12.5%
Assets, Current 11.6M USD +14.6%
Property, Plant and Equipment, Net 34K USD -54.7%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 11.6M USD +12.8%
Accounts Payable, Current 406K USD -28.9%
Employee-related Liabilities, Current 232K USD -82.4%
Accrued Liabilities, Current 1.25M USD -49.1%
Liabilities, Current 1.66M USD -46.2%
Retained Earnings (Accumulated Deficit) -172M USD -3.42%
Stockholders' Equity Attributable to Parent 9.93M USD +38%
Liabilities and Equity 11.6M USD +12.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.49M USD +53%
Net Cash Provided by (Used in) Financing Activities 6.57M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 5.97M shares +97.9%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.08M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.9M USD +25.2%
Deferred Tax Assets, Valuation Allowance 132M USD -0.28%
Deferred Tax Assets, Gross 132M USD -0.28%
Operating Lease, Liability 19K USD -47.2%
Depreciation 10K USD +42.9%
Lessee, Operating Lease, Liability, to be Paid 19K USD -48.6%
Operating Lease, Liability, Current 0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1K USD -50%
Deferred Tax Assets, Operating Loss Carryforwards 106M USD +1.72%
Additional Paid in Capital 182M USD +4.84%
Preferred Stock, Shares Outstanding 1 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.92M USD -11%
Interest Expense 5K USD -44.4%